Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEST study of bosutinib in elderly chronic-phase chronic myeloid leukemia after failure of first-line TKI
2016-002216-40Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bosutinib in chronic myelogenous leukemia (CML), sponsored by GIMEMA. Primary endpoint: Major molecular response rate at 52 weeks. Started Jun 2021; status: completed.
02
Drugs
bosutinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2016-002216-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002216-40.